WEST LAFAYETTE, Ind., July 07, 2022 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in non-clinical and analytical drug discovery and development services and research models and related products and services, today announced that the company has completed the purchase of Protypia, Inc. (“Protypia”), basée à Nashville, Tennessee. Protypia is an emerging protein/peptide bioanalytical company that offers high quality targeted tissue mass spectrometry for proteins and peptides.
“Adding Protypia’s quantitative large molecule tissue-based bioanalytical capabilities to Inotiv’s already established mass spectrometry-based bioanalytical offerings will allow customers to translate their clinical findings into their discovery and preclinical pipelines and will be highly complementary. to the GLP biomarker capabilities that Inotiv is currently building at their Rockville, MD facility,” said Daniel Liebler, Founder, President and CEO of Protypia. “Furthermore, biopsy-based protein characterization has the potential to segment patient populations for inclusion in clinical trials investigating the specific mechanisms of action of new therapies. Such segmentation of patients will increase the probability of success of molecules entering clinical development at an advanced stage. »
John Sagartz, Chief Strategy Officer of Inotiv, added: “This highly specialized technology and know-how greatly enhances our ability to support our customers in the development of safe and effective drugs, particularly in the areas of immuno -oncology and cell and gene therapy. The ability to accurately quantify protein levels in tissues, including paraffin-embedded tissues, opens up exciting new avenues for scientists to explore when studying disease pathways.
The consideration for the transaction was approximately $11.0 million, consisting of approximately $9.5 million in cash, common stock of Inotiv worth approximately $0.9 million dollars et de 0,6 million de dollars en billets à ordre subordonnés non garantis.
The company plans to retain all current Protypia employees and maintain operations in Nashville, TN.
Inotiv, Inc. is a premier contract research organization dedicated to providing nonclinical and analytical drug discovery and development services, research models, and related products and services. The Company’s products and services aim to bring new drugs and medical devices through the discovery and preclinical development phases, while increasing efficiency, improving data and reducing the cost of bringing new products to market. medications. Inotiv is committed to supporting discovery and development goals as well as helping researchers realize the full potential of their critical R&D projects, while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties, including, but not limited to, risks and uncertainties relating to changes in the market and demand for our products and services, the development, marketing and sale of products and services, changes in technology, industry and regulatory standards, The calendar of acquisitions and the success of their closure, their integration and their commercial and financial impact, government regulations, inspections and investigations, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in Company filings auprès de la Securities and Exchange Commission des États-Unis.